Therapeutic advances in drug safety
2025
Gilmar Gutierrez, Gustavo Vazquez, Nisha Ravindran et al.
5 citations
Intranasal (IN) esketamine has become an effective and well-tolerated therapeutic option for the management of treatment-resistant depression within major depressive disorder (MDD-TRD). Despite these promising benefits, given the prevalence of ketamine abuse, concerns remain over the addiction liability that may be associated with esketamine treatment. The objective of this study is to assess...
Psychiatry Research
October 1, 2024
Gilmar Gutierrez, Jennifer Swainson, Nisha Ravindran et al.
17 citations
Intravenous (IV) ketamine and intranasal (IN) esketamine are novel therapies to manage treatment resistant depression within major depressive disorder (MDD-TRD). This is a multi-site observational study aiming to assess the real-world effectiveness and tolerability of these novel therapies in the management of MDD-TRD. 53 patients were referred to receive IV ketamine (n = 26, 69.23 % female,...
BMJ Open
September 1, 2022
Gustavo Vazquez, Gilmar Gutierrez, Joshua D. Rosenblat et al.
6 citations
INTRODUCTION: Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits. The objective of this observational study is to elucidate the association of intranasal (IN) esketamine with beneficial and negative outcomes in the management of...
The Canadian Journal of Psychiatry
November 11, 2020
Jennifer Swainson, Alexander McGirr, Pierre Blier et al.
109 citations
OBJECTIVE: -methyl-d-aspartate (NMDA) receptor antagonist, has demonstrated rapid antidepressant effects in patients with TRD. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to review the evidence for efficacy and safety of racemic ketamine and to provide recommendations for its use in clinical practice. METHODS: A systematic review was conducted with...
Sri Lanka Journal of Psychiatry
June 18, 2020
Nisha Ravindran, Arun Ravindran
A significant proportion of patients with major depressive disorder are refractory to approved interventions. The first report of significant and rapid benefit of intravenous (IV) ketamine for treatment resistant depression (TRD) appeared in 2000. Since then, there have been multiple reports on the efficacy and tolerability of ketamine formulations for TRD, in particular for single-dose IV...